Leprosy
Leprosy is caused by a slow-growing bacillus, Mycobacterium leprae. It is transmitted via droplets from the nose and mouth of untreated patients with severe disease, but is not highly infectious. If left untreated, the disease can cause nerve damage, leading to muscle weakness and atrophy, and permanent disabilities.
Leprosy can be easily treated with a 6–12-month course of multidrug therapy. The treatment is highly effective, and has few side-effects and low relapse rates; there is no known drug resistance.
Information campaigns about leprosy in high risk areas are crucial so that patients and their families, who were historically ostracized from their communities, are encouraged to come forward and receive treatment. The most effective way of preventing disabilities in leprosy, as well as preventing further transmission of the disease, lies in early diagnosis and treatment with MDT.
TDR related research
Currently, TDR has no research on this disease.
Latest news
-
Pipeline grows for neglected diseases research and development (R&D)
4 February 2013 -
Resolution on neglected tropical diseases to be recommended to WHO Health Assembly
29 January 2013 -
WHO releases updates on targets to reduce NTDs
16 January 2013
Publications and articles
-
Changing Mindsets: Research Capacity strengthening in low and middle-income countries
1 November 2010 -
A human rights-based approach to neglected tropical diseases
20 February 2009 -
Strategic and business plan for the African Network for Drugs and Diagnostics Innovation (ANDI)
Creating a sustainable platform for R&D innovation in Africa
1 January 2009
Related WHO information
- Leprosy elimination and the "Final Push" strategy
- Leprosy: global situation
-
WHO Leprosy Forum Report
May 2006 [PDF 230kb] -
International travel and health
Publication on travel risks, precautions and vaccination requirements